Introduction and Scale‑up of the Dapivirine Vaginal Ring, Long‑Acting Injectable Cabotegravir and Lenacapavir for HIV Prevention in Eswatini Implementation Plan Version II, 2025-2030

10 July 2026

This PrEP Implementation Plan, developed by Eswatini’s Ministry of Health, is a strategic roadmap to guide Eswatini’s scale-up of HIV prevention. It translates global WHO guidance and national commitments into actionable steps, ensuring that oral PrEP, the dapivirine vaginal ring, and long-acting injectables such as cabotegravir and lenacapavir are introduced in a coordinated, evidence-based way. By setting priorities and defining delivery models, the plan ensures that PrEP is accessible, acceptable, and tailored to the diverse needs of populations most at risk.

Featured Resources

External Link

LEN Learning Clinic Resources

These interactive learning clinics, hosted by CHAI and Wits RHI, bring together governments, implementing partners, and technical assistance teams to share and discuss early insights from LEN introduction, including practical service delivery innovations and clinical considerations. All resources from learning clinics will be added here as they take place. See the Events page for upcoming…

Document

LEN Rollout Resources and Tools

The resources listed in this document, alongside insights drawn from the report Getting PrEP Rollout Right This Time, can support countries in the early stages of LEN planning. These tools are being disseminated as part of a coordinated effort between AVAC, CHAI, CIFF, the Global Fund, PEPFAR, PSI, Unitaid, Wits RHI, and WHO under the…

Document

Nigeria National HIV Prevention Plan 2026–2030

This plan, developed by Nigeria’s Federal Ministry of Health and Social Welfare and National Agency for the Control of AIDS, provides a roadmap for reversing the HIV epidemic in Nigeria.

Document

Ghana National HIV Prevention Roadmap, 2026-2028

This National HIV Prevention Roadmap 2026-2028 outlines Ghana’s HIV and AIDS prevention measures which are based on the five core prevention pillars -Adolescent Girls and Young Women, Adolescent Boys and Young Men, Vulnerable Populations, Condoms, and Anti-Retroviral based Prevention.

Document

Implementation Guide for Clinicians on the Delivery of Long-Acting Injectable Pre-Exposure Prophylaxis in Zimbabwe, 2026

These clinical guidelines, developed by Zimbabwe’s Ministry of Health and Child Care in 2026, can be used to support delivery of injectable lenacapavir (LEN) and cabotegravir (CAB).

Document

Mozambique Guidelines for Combined Biomedical Prevention of HIV, STIs, and Viral Hepatitis, 2025

These clinical guidelines, developed by Mozambique’s Ministry of Health in 2025, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).

Document

Lesotho Addendum to HIV Prevention, Treatment, and Care Guidelines, 2026

These clinical guidelines, developed by Lesotho’s Ministry of Health in 2026, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).

Document

Eswatini Pre-Exposure Prophylaxis Implementation Guidelines, 2025

These implementation guidelines, developed by Eswatini’s Ministry of Health in 2025, can be used to support delivery of PrEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).

External Link

Long-Acting Injectable Cabotegravir Use and Persistence Over Two Years

This article from JAMA Network Open explores levels of cabotegravir for PrEP uptake and persistence in the US since approval by the US Food and Drug Administration in December 2021.

External Link

Drivers of Vertical HIV Transmission in Sub-Saharan Africa and the Impact and Cost-Effectiveness of Targeted and Universal Lenacapavir Pre-Exposure Prophylaxis

This article from Journal of the International AIDS Society evaluates drivers of vertical transmission in Sub Saharan Africa and assesses the impact and cost-effectiveness of lenacapavir for PrEP amongst pregnant and lactating people without HIV.